Visit the Beamex web site
Click on the advert above to visit the company web site

Product category: Pharmaceutical Processing News
News Release from: NNE (Novo Nordisk Engineering)
Edited by the Processingtalk Editorial Team on 21 December 2006

NNE acquires Germany-based Pharmaplan

Request your FREE weekly copy of the Processingtalk email newsletter. News about Pharmaceutical Processing News and more every issue. Click here for details.

The international life science engineering and consultancy company, NNE, has reached agreement with Fresenius ProServe to acquire its subsidiary, the Germany-based engineering company Pharmaplan

The international life science engineering and consultancy company, NNE, has reached an agreement with the health care group Fresenius ProServe to acquire its subsidiary, the Germany-based engineering company Pharmaplan The two companies will unite under the name of NNE Pharmaplan

Both NNE and Pharmaplan operate in the biotechnology and pharmaceutical industries, and by joining forces they will become one of the world's leading companies in that field of engineering.

According to NNE President, Hans Ole Voigt, the two companies - both rooted in the pharmaceutical industry - "are a perfect match.

Our market presence, services and areas of expertise are complementary, and therefore the synergies from the merger mean that the whole will be greater than the sum of its parts.

This will enable us to pursue growth and allow NNE Pharmaplan to become the preferred partner of the international pharma and biotech industries", continues Hans Ole Voigt.

With more than 1,500 employees specialised in pharmaceutical engineering and subsidiaries and sales offices in 15 countries, NNE Pharmaplan will be able to offer an all-encompassing portfolio of consultancy and engineering services in all markets significant to the pharmaceutical industry.

"With global reach and a large, highly skilled resource pool we will be able to serve the multinational pharmaceutical companies on a worldwide basis and be a very strong candidate for executing large-scale pharmaceutical projects", says Hans Ole Voigt.

Pharmaplan supplements NNE with know-how in delivery of turnkey facilities, validation and key pharmaceutical processes, whereas NNE supplements Pharmaplan within areas such as biotechnology, cleanrooms and automation.

Financially, NNE Pharmaplan will have a turnover above euro 200 million, as NNE turnover in 2005 was euro 163 million and that for Pharmaplan euro 49 million.

NNE Pharmaplan will be headquartered in Copenhagen, Denmark, but will have a significant European hub in the current Pharmaplan offices in Oberursel, Germany, near Frankfurt.

"From here we plan to expand our business into central Europe, which will become an increasingly important market for pharmaceutical and biotechnology companies in the course of the coming years", says Hans Ole Voigt.

The acquisition is effective as of 1 January 2007, but will have to await final anti-trust approval before it can be finally implemented.

This is anticipated to happen in the first quarter of 2007.

Until then the two companies will continue to operate separately.

NNE (Novo Nordisk Engineering): contact details and other news
Email this article to a colleague
Register for the free Processingtalk email newsletter
Processingtalk Home Page

Search the Pro-Talk network of sites

Visit the Beamex web site